Learning Center
Plans & pricing Sign in
Sign Out

Research and Development - Dr Tony Soteriou_1_


									        Research and Development
                        Dr Tony Soteriou
                  AWP, Director of Research and

enabling and empowering people to reach their potential and live fulfilling lives
 AWP Research and Development

• AWP is a centre of excellence for NHS
• MH Trust with highest research activity in
  South West and surrounding
  – 3rd largest allocation of NIHR support funding
    after SLAM and Manchester
• Trust R&D income
  – £3m in 2009/10 (increase of 35% on 2008/9)
• 127 projects live in 2008/9
   – 70 Non-Commercial
   – 35 Student
   – 22 Commercial projects
• Board-approved R&D Strategy and R&D within Trust
  Strategic Objectives
   – Trust reputation, effective and cost-effective services
• University Links
   – Bristol, Bath, UWE, others nationally including
     Imperial College, Manchester, Oxford
                             Research Across Strategic Business Units

Number of Projects

                     30                                                          Student
                     25                                                          Com
                     20                                                          Non-Com
                          AOWA   OP      SDAS       SP &        CAMHs   >1 SBU
                                      Strategic Business Unit
   Assessment by Department of
• DH assessment of AWP 2008 R&D
  – ‘This is an excellent report and it is good to
    see that R&D continues to have a high profile
    within the Trust. The report highlights some
    very interesting impacts for patients as a
    consequence of research carried out by the
Best Research for Best Health, Department of Health 2006
         National Picture

Highlighted the
importance of R&D to
innovation in the NHS
             National Picture
NHS ambition for all NHS providers to increase
participation in NHS research and to “double the
number of patients taking part in NHS trials within
in 5 years”.
….”through its commitment to
innovation and to the promotion and
conduct of research”. Furthermore,
the Handbook to the NHS
Constitution highlighted that “The
NHS will do all it can to ensure that
patients, from every part of
England, are made aware of
research that is of particular
relevance to them…….putting in
place procedures to ensure that
patients are notified of opportunities
to join in relevant ethically approved
    Research and Level of Mental Health

A review of
UK health research funding, Sir David Cooksey 2006
             AWP R&D Strategy
• Approved by the Board in November 2007
  – Board reiterated support for R&D in July 09
• Aligned with Best Research For Best Health
  – Highest quality R&D
     •   Properly funded
     •   National or International
     •   Generalisable
     •   Undertaken by appropriately trained staff
     •   Collaborations with universities and industry
  – Research should be externally funded
     • Non-commercial or Commercial
     • Medical Research Council, Department of Health, Charities
       (e.g. Big Lottery, Wellcome Trust)
     • Industry
  – Undertaken as part of university courses
            Research Networks
• Western Comprehensive Local Research Network
  – R&D Support funding, RM&G funding, national standards
• South West Research Networks – Hosted by AWP
  – Mental Health
  – South West Dementias and Neurodegenerative Diseases
     • Multicentre projects will get adopted by networks
     • Clinical studies officers to help recruitment, start-up
  – With MHRN
     • 62% of our portfolio is generated from outside the mental health
       research concentrated areas of the South London-Manchester axis
     • The median sample size of studies: now 234; 5 times previous
       average for a mental health study
     • Recruitment to target
         – 91% studies (n=11) recruited to funder’s target, 3 exceeded recruitment
Why Networks are Needed for NHS

Work involved to recruit participants to a pilot therapy trial (taken from MHRN
review, 2007)
           AWP R&D Office
• Research Governance Approvals
  – Contracts, SBU agreements, pharmacy, costing
  – Reduced bureaucracy, national standards
  – Adopt national costing, contracts, etc.
• Point of contact for all Trust R&D: non-
  commercial and commercial
• Support R&D delivery: start-up, recruitment
• Manage distribution of NHS R&D support
  funding to SBUs
 Research Governance Approvals
• Protocol
  – External Funding
  – Undertaken as part of University Course
  – University Collaboration and Research
• Research Sponsor
• NHS Research Ethics Favourable Opinion
• Other Regulatory Approvals
  – MHRA, Radiation etc
• AWP Trust R&D Approval
Research Governance Approvals
      Supporting Engagement
• Service User, Carer and Public
  – Service User Research Forum
  – Bristol-wide PPI scoping study
  – Service user/carer-led research e.g. Bristol MIND
• Staff involvement
  – Nursing, Medical, clinical psychology, arts
    psychotherapy, OT, physiotherapy, HR, managers
  – Recruitment in research project
  – Staff research in collaboration with universities
    Research Design Service
 – NIHR funding, South West coverage
 – Free support for grant applications to NIHR
   funding schemes
        Influencing Practice

• AWP Peer review publications
  – 2008: 100
  – 2007: 85
  – 2006: 91
• Conference and professional meetings
• R&D inputting into Trust service and
  treatment planning and design
          AWP influencing practice
• Trazodone in sleep disorders and depression
   – Led to changes in prescribing practice for depression and sleep
• R&D in W. Wilts on addiction treatment grounded in family focused
   – Team now inviting family members to assessments, offering family
     members support (using the 5-step family intervention).
   – In National Treatment Agency's 2008 Commissioner guidance.
• Using Arts to Enhance Mental Healthcare Environments
   – Commissioning good practice checklist and on NHS Knowledge and
     Information Portal.
• Suicide prevention programme
   – Findings informing policy concerning use of this co-proxamol and
     suicide prevention.
Research and Development and

Basic R&D:      Proof of   Initial         Large Scale        Change in
Novel           Concept/   evidence of     pragmatic R&D:      Practice/
interventions   Efficacy   effectiveness   proving            Improved
                                           effectiveness in   Outcomes
                                           real settings

                     R&D Pathway                              Health

To top